Suven Life Scienes secures Patents

Suven Life Sciences Ltd on October 23, 2007 announced that the Indian Patent Office had granted three Product Patents 208688, 208714 and 209540 corresponding to three New Chemical Entities (NCEs) for the treatment of disorders associated with Neuro degenerative diseases and theses Patents are valid until 2022.

The granted claims of the patents include the class of selective 5-HT compounds discovered by the Company are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzhemier's, Attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia.

The Company thus far has filed 25 product patents under PCT out if which 10 has entered national phase. These are the first Product Patents granted to the Company from its four years of drug discovery efforts.

The Company has already filed its Investigational New Drug (IND) application of DCGI to conduct the clinical Phase-I study on their developmental candidate SUVN-502.

We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential, says Venkat Jasti, CEO of the Company.

The Company, since Sept-2006 is also working as a collaborative Research Partner (CRP) with Elli Lilly to Discover and Develop NCE's for an unmet medical need in CNS therapeutic area.

Suven is a major service provider of Durg Discovery and Development support Services (DDDSS) to global Pharmaceutical, Life Sciences and Biotech Companies in additional to their continued business interest an growth in Contract Research and Manufacturing Services (CRAMS).